Computational Study of Trisindoline 5 Against Overexpressed EGFR Protein on Breast Cancer Stem Cell

The current treatment to control the proliferation rate of breast cancer is still not optimal due to the presence of breast cancer stem cells (BCSCs) which are resistant to several chemotherapy agents. Epidermal Growth Factor Receptor (EGFR) may promote the survival of BCSCs. The existing inhibitory...

Full description

Saved in:
Bibliographic Details
Main Authors: Nurhayati A.P.D., Fatoni M., Santoso M., Wati F.A.
Format: Article
Language:English
Published: EDP Sciences 2025-01-01
Series:BIO Web of Conferences
Online Access:https://www.bio-conferences.org/articles/bioconf/pdf/2025/08/bioconf_srcm24_05010.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1825206590032052224
author Nurhayati A.P.D.
Fatoni M.
Santoso M.
Wati F.A.
author_facet Nurhayati A.P.D.
Fatoni M.
Santoso M.
Wati F.A.
author_sort Nurhayati A.P.D.
collection DOAJ
description The current treatment to control the proliferation rate of breast cancer is still not optimal due to the presence of breast cancer stem cells (BCSCs) which are resistant to several chemotherapy agents. Epidermal Growth Factor Receptor (EGFR) may promote the survival of BCSCs. The existing inhibitory drugs used to treat the EGFR that act as the master regulator of the signaling network still have a limited response in breast cancer. Trisindoline is an indole trimer alkaloid natural compound that provide a cytotoxic effect on cancer cells. In 2021, modification of trisindoline has been synthesized into trisindoline 5. This study aims to analyze the interaction between trisindoline 5 and EGFR through in silico. Data retrieval trisindoline 5 using ChemDraw, doxorubicin as positive control from PubChem, EGFR from RCSB database. Docking was done using AutoDock Vina and the results were visualized using Biovia Discovery Studio. The binding affinity of trisindoline 5 is lower than doxorubicin to the EGFR. Trisindoline 5 can inhibit EGFR binding site on some amino acids and forms hydrogen bonds that predicted to be more stable. This research informed that trisindoline 5 might be potential for developing novel therapeutic drug against BCSCs.
format Article
id doaj-art-bb1bf2f766f34bf5b332fa1232463936
institution Kabale University
issn 2117-4458
language English
publishDate 2025-01-01
publisher EDP Sciences
record_format Article
series BIO Web of Conferences
spelling doaj-art-bb1bf2f766f34bf5b332fa12324639362025-02-07T08:20:29ZengEDP SciencesBIO Web of Conferences2117-44582025-01-011570501010.1051/bioconf/202515705010bioconf_srcm24_05010Computational Study of Trisindoline 5 Against Overexpressed EGFR Protein on Breast Cancer Stem CellNurhayati A.P.D.0Fatoni M.1Santoso M.2Wati F.A.3Department of Biology, Faculty of Science and Data Analytics, Institut Teknologi Sepuluh NopemberDepartment of Biology, Faculty of Science and Data Analytics, Institut Teknologi Sepuluh NopemberDepartment of Chemistry, Faculty of Science and Data Analytics, Institut Teknologi Sepuluh NopemberDepartment of Chemistry, Faculty of Mathematics and Natural Science, Universitas Negeri Surabaya, Ketintang, SurabayaThe current treatment to control the proliferation rate of breast cancer is still not optimal due to the presence of breast cancer stem cells (BCSCs) which are resistant to several chemotherapy agents. Epidermal Growth Factor Receptor (EGFR) may promote the survival of BCSCs. The existing inhibitory drugs used to treat the EGFR that act as the master regulator of the signaling network still have a limited response in breast cancer. Trisindoline is an indole trimer alkaloid natural compound that provide a cytotoxic effect on cancer cells. In 2021, modification of trisindoline has been synthesized into trisindoline 5. This study aims to analyze the interaction between trisindoline 5 and EGFR through in silico. Data retrieval trisindoline 5 using ChemDraw, doxorubicin as positive control from PubChem, EGFR from RCSB database. Docking was done using AutoDock Vina and the results were visualized using Biovia Discovery Studio. The binding affinity of trisindoline 5 is lower than doxorubicin to the EGFR. Trisindoline 5 can inhibit EGFR binding site on some amino acids and forms hydrogen bonds that predicted to be more stable. This research informed that trisindoline 5 might be potential for developing novel therapeutic drug against BCSCs.https://www.bio-conferences.org/articles/bioconf/pdf/2025/08/bioconf_srcm24_05010.pdf
spellingShingle Nurhayati A.P.D.
Fatoni M.
Santoso M.
Wati F.A.
Computational Study of Trisindoline 5 Against Overexpressed EGFR Protein on Breast Cancer Stem Cell
BIO Web of Conferences
title Computational Study of Trisindoline 5 Against Overexpressed EGFR Protein on Breast Cancer Stem Cell
title_full Computational Study of Trisindoline 5 Against Overexpressed EGFR Protein on Breast Cancer Stem Cell
title_fullStr Computational Study of Trisindoline 5 Against Overexpressed EGFR Protein on Breast Cancer Stem Cell
title_full_unstemmed Computational Study of Trisindoline 5 Against Overexpressed EGFR Protein on Breast Cancer Stem Cell
title_short Computational Study of Trisindoline 5 Against Overexpressed EGFR Protein on Breast Cancer Stem Cell
title_sort computational study of trisindoline 5 against overexpressed egfr protein on breast cancer stem cell
url https://www.bio-conferences.org/articles/bioconf/pdf/2025/08/bioconf_srcm24_05010.pdf
work_keys_str_mv AT nurhayatiapd computationalstudyoftrisindoline5againstoverexpressedegfrproteinonbreastcancerstemcell
AT fatonim computationalstudyoftrisindoline5againstoverexpressedegfrproteinonbreastcancerstemcell
AT santosom computationalstudyoftrisindoline5againstoverexpressedegfrproteinonbreastcancerstemcell
AT watifa computationalstudyoftrisindoline5againstoverexpressedegfrproteinonbreastcancerstemcell